Exelixis, Inc. EXEL today reported positive preliminary data from the
cohort of hepatocellular carcinoma patients participating in the ongoing
phase 2 randomized discontinuation trial of cabozantinib. Allan Lee
Cohn, M.D., Medical Director of Research at the Rocky Mountain Cancer Centers,
will present the data today at 11:45 a.m. PST as part of the 2012
Gastrointestinal Cancers Symposium. The meeting is taking
place in San Francisco, California.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in